Cyclooxygenase-2 inhibitors dilemma in cardiovascular medicine: are all family members bad players?
Cyclooxygenase-2 (COX-2) inhibitors dilemma in cardiovascular medicine has not been resolved yet. The cardiovascular safety of selective COX-2 inhibitors other than rofecoxib is uncertain. Given the ongoing controversy surrounding the use of COX-2 inhibitors, further clinical studies with different types of drugs are required to establish safety and therapeutic benefit in patients with coronary artery disease.